The urgency behind this work is difficult to overstate. The World Health Organization has warned that the world is effectively running out of antibiotics, listing the surge in antimicrobial resistance among the top ten threats to global public health. Multidrug-resistant bacteria, defined as those resistant in vitro to at least one agent in three or more antimicrobial categories, are emerging so quickly that existing drugs are losing their clinical value. Against that backdrop, the discovery of entirely new chemical scaffolds with measurable antibacterial activity and acceptable predicted safety is a notable step forward.

To measure activity, the researchers turned to a resazurin-based microdilution assay, a sensitive colorimetric technique performed in 96-well plates. Resazurin is a blue dye that living bacteria convert to a pink, reduced form as they metabolize; if a well stays blue after incubation, the bacteria in it have been inhibited. Each of the nine derivatives was serially diluted across the plate, and minimum inhibitory concentrations (MICs) were recorded alongside minimum bactericidal concentrations (MBCs), which capture the concentration needed to kill rather than merely stall the bacteria. The assay itself was validated against the standard antibiotic gentamicin, with results matching Clinical Laboratory Standards Institute and EUCAST reference values.

The headline result came from derivative 6, which achieved an MIC of just 0.0048 mg/mL against S. typhimurium—the lowest value in the entire series and, notably, lower than the MIC of gentamicin against the same organism. All nine derivatives showed broad-spectrum activity in the range of 0.0048 to 0.620 mg/mL, and derivatives 1, 4, 6, 8, and 9 were active against both Gram-negative species such as Escherichia coli, Salmonella typhimurium, and Klebsiella aerogenes and Gram-positive organisms including Bacillus cereus and Enterococcus faecalis. Statistical analysis using geometric means confirmed derivative 6 as the most active synthesized compound, followed by derivative 4, while derivative 7 ranked as the weakest.

One intriguing pattern emerged from the structure–activity data: potency did not track neatly with substituent chemistry. Derivatives sharing the same benzyl substituent at the R2 position, for example, varied widely in efficacy, and compounds with nearly identical R1 and R2 groups differed in activity. The authors attribute this to structural differences interacting with variations in bacterial cell wall architecture and pathogen-specific resistance mechanisms. Across all compound–organism pairs, the MBC was roughly five times the MIC, indicating that the molecules are primarily bacteriostatic at inhibitory concentrations and require a modest dose increase to deliver a killing blow.

To probe how these molecules might work at the molecular level, the team performed molecular docking against peptidoglycan glycosyltransferase, an enzyme central to bacterial cell wall assembly. Peptidoglycan forms the rigid backbone of the bacterial cell wall, and glycosyltransferase domains within penicillin-binding proteins polymerize glycan chains from lipid-linked precursors. Blocking this process causes osmotic instability and, ultimately, cell lysis—a mechanistically attractive target that many successful antibiotics already exploit. The docking protocol was validated by redocking the crystal structure’s native ligand, which reproduced the original binding pose and its key hydrogen bonds with residues including Glu83, Ser116, and Gln121.

When the synthetic derivatives were docked, derivative 6 again stood out, achieving a binding energy of −6.958 kcal/mol, the strongest among the series. Its benzene and pyridine rings, along with the indole heterocycle, packed into the binding pocket via hydrophobic interactions with Lys62, Tyr65, and Leu159, supplemented by a π–cation contact with Lys62 and π–π stacking with Tyr65. The nitrogen and oxygen atoms of the oxazepine ring are thought to facilitate hydrogen bonding within glycosyltransferase active sites, while related indole compounds have been shown to disrupt membrane potential, deplete ATP pools, interfere with exopolysaccharide production, and suppress biofilm formation—multiple complementary mechanisms wrapped into a single scaffold.

Potency means little if a drug candidate poisons the patient, so the team deployed a comprehensive in silico safety workup. The CLC-Pred platform screened all nine derivatives for cytotoxicity across a panel of 198 human cell lines, and none exceeded the 0.5 probability-of-activity threshold conventionally associated with likely toxicity. Mean activity probabilities ranged only from 0.219 to 0.253, and normal cell lines such as skin and lung fibroblasts showed significantly lower predicted activity (Pa = 0.151) than tumor-derived lines (Pa = 0.249), hinting at a selectivity margin in favor of healthy tissue. Quantitative structure–activity/toxicity modeling predicted every derivative to be inactive for cytotoxicity, mutagenicity, and carcinogenicity.

Pharmacokinetic predictions proved equally encouraging. SwissADME analysis showed that most derivatives are highly absorbed in the gastrointestinal tract, and derivative 5 emerged as the standout from a drug-likeness perspective, with a Log P of 2.50—comfortably within the lipophilicity window defined by Lipinski’s Rule of Five—and zero violations. Derivative 5 was therefore flagged as the safest, most balanced lead for future structural optimization, while derivative 6 remains the potency champion. Compared with gentamicin, derivative 6 still required roughly 3.7-fold higher concentrations by geometric-mean MIC, so there is room for medicinal chemists to close the gap.

As with all early-stage discovery work, the caveats matter: these safety and mechanistic conclusions rest on computational prediction and in vitro assays, and the authors emphasize that in vitro cytotoxicity validation must confirm the predicted margins before any move toward preclinical development. Still, the study delivers exactly what the antibiotic pipeline desperately needs—a validated new chemical class with demonstrable broad-spectrum activity, a plausible cell-wall-targeting mechanism, and a computational safety profile clean enough to justify further investment. Whether derivative 6 or its optimized descendants eventually reach the clinic, the oxazepino–indole hybrid scaffold has now earned its place on the list of structures worth watching in the fight against drug-resistant bacteria.

Subject of Research: Antibacterial activity, molecular docking, and in silico safety profiling of novel indole-fused oxazepine derivatives

Article Title: Antibacterial activity, molecular docking, and in silico safety profiling of novel 3,10-dihydro- 2H -1,3-oxazepino[7,6- b ]indole derivatives

Article References: Sammor, M. S., Abu-Halaweh, M. M., Al Abrouni, K., Chandrasekaran, B., Dahadha, A., & Khazaleh, N. (2026). Antibacterial activity, molecular docking, and in silico safety profiling of novel 3,10-dihydro-2H-1,3-oxazepino[7,6-b]indole derivatives. Pharmacia, 73, Article e199777. https://doi.org/10.3897/pharmacia.73.e199777

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e199777

Keywords: antibiotic resistance, indole, oxazepine, minimum inhibitory concentration, molecular docking, peptidoglycan glycosyltransferase, QSAR, SwissADME, drug-likeness, Salmonella typhimurium, cytotoxicity prediction, drug discovery